Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial.

Vasc Health Risk Manag · 2007 · PMC1994030 · PMID 17580734

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

Assessment of daily compliance by MEMS The difference in the percentage of days with the correct number of doses taken between the groups was highly significant in favor of the betaxolol group (84.4% vs 64.0%, p < 0.0001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.